非戈替尼治疗中重度类风湿关节炎长达8.3年治疗期间的综合安全性分析
该研究整合7项试验、3691例中重度类风湿关节炎患者,非戈替尼100 mg或200 mg每日一次,中位暴露3.8年(最大8.3年,共12541患者年)。总体人群中关注的治疗中出现的不良事件随时间稳定且两剂量可比,仅带状疱疹在100 mg组数值上低于200 mg组;≥65岁患者中恶性肿瘤与全因死亡率呈剂量依赖趋势。
要点
- 总体人群中严重感染、恶性肿瘤、主要不良心血管事件和静脉血栓栓塞发生率随时间稳定且两剂量可比。
- 带状疱疹发生率在非戈替尼100 mg组数值上低于200 mg组(1.1 vs 1.5/100患者年)。
- ≥65岁患者严重感染、带状疱疹、主要不良心血管事件、恶性肿瘤和全因死亡率均高于<65岁患者。
核心结论
- 总体人群中关注的治疗中出现的不良事件随时间稳定,非戈替尼100 mg与200 mg剂量组间相似,带状疱疹除外。
- 在≥65岁患者中提示恶性肿瘤与全因死亡率存在剂量依赖关系。
研究设计与样本
- 整合7项试验(NCT01888874、NCT01894516、NCT02889796、NCT02873936、NCT02886728、NCT02065700和NCT03025308)的数据。
- 患者接受非戈替尼100 mg或200 mg每日一次,共3691例,中位(最大)暴露3.8(8.3)年,累计12541患者年。
- 计算治疗中出现的不良事件的暴露调整发生率(EAIR)/100患者年,并对<65岁和≥65岁患者进行事后分析。
主要发现
- 总体人群中严重感染、恶性肿瘤、主要不良心血管事件和静脉血栓栓塞的EAIR随时间稳定且两剂量可比。
- 总体人群中带状疱疹EAIR(95%CI)/100患者年:非戈替尼100 mg组1.1(0.8至1.5) vs 200 mg组1.5(1.2至1.8),100 mg组数值上较低。
- ≥65岁患者相比<65岁患者,严重感染、带状疱疹、主要不良心血管事件、恶性肿瘤和全因死亡率更高。
- ≥65岁患者中,非黑色素瘤皮肤癌EAIR(95%CI)/100患者年:100 mg组0.4(0.1至1.1) vs 200 mg组1.4(0.8至2.2),100 mg组数值上较低。
- ≥65岁患者中,排除非黑色素瘤皮肤癌的恶性肿瘤EAIR(95%CI)/100患者年:100 mg组1.0(0.5至1.9) vs 200 mg组2.0(1.3至2.9),100 mg组数值上较低。
关键数值与推荐
- 非戈替尼100 mg与200 mg每日一次。
- 带状疱疹EAIR(95%CI)/100患者年:100 mg组1.1(0.8至1.5) vs 200 mg组1.5(1.2至1.8)。
- ≥65岁患者非黑色素瘤皮肤癌EAIR(95%CI)/100患者年:100 mg组0.4(0.1至1.1) vs 200 mg组1.4(0.8至2.2)。
- ≥65岁患者排除非黑色素瘤皮肤癌的恶性肿瘤EAIR(95%CI)/100患者年:100 mg组1.0(0.5至1.9) vs 200 mg组2.0(1.3至2.9)。
- ≥65岁患者全因死亡率EAIR(95%CI)/100患者年:100 mg组1.3(0.7至2.2) vs 200 mg组1.6(1.0至2.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To update the long-term safety profile of filgotinib, a Janus kinase-1 preferential inhibitor, in patients with moderate-to-severe rheumatoid arthritis. METHODS: Data from seven trials were integrated (NCT01888874, NCT01894516, NCT02889796, NCT02873936, NCT02886728, NCT02065700 and NCT03025308). Patients received once-daily filgotinib 100 mg or 200 mg. Exposure-adjusted incidence rates (EAIRs)/100 patient-years of exposure (PYE) were calculated for treatment-emergent adverse events (TEAEs). Post hoc analyses assessed patients aged <65 and ≥65 years. RESULTS: Patients (N=3691) received filgotinib for a median (maximum) of 3.8 (8.3) years (12 541 PYE). Rates of TEAEs of interest: serious infections, malignancies, major adverse cardiovascular events (MACE) and venous thromboembolism were stable over time and comparable between doses. In the overall population, numerically lower EAIR (95% CI)/100 PYE of herpes zoster was observed for filgotinib 100 mg versus 200 mg (1.1 (0.8 to 1.5) vs 1.5 (1.2 to 1.8)). Incidence of serious infections, herpes zoster, MACE, malignancies and all-cause mortality was higher in patients aged ≥65 versus <65 years. In patients aged ≥65 years, EAIRs (95% CI)/100 PYE for non-melanoma skin cancer (NMSC) (0.4 (0.1 to 1.1) vs 1.4 (0.8 to 2.2)), malignancies excluding NMSC (1.0 (0.5 to 1.9) vs 2.0 (1.3 to 2.9)) and all-cause mortality (1.3 (0.7 to 2.2) vs 1.6 (1.0 to 2.5)) were numerically lower for filgotinib 100 mg versus 200 mg. CONCLUSIONS: In the overall population, TEAEs of interest were stable over time and similar between filgotinib 100 mg and 200 mg dose groups, except for herpes zoster. A dose-dependent relationship between malignancies and all-cause mortality was suggested in patients ≥65 years old.
引用
- Burmester GR, Gottenberg JE, Caporali R, et al. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years. Ann Rheum Dis. 2024. PMID: 38782549. doi:10.1136/ard-2024-225759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。